Table 1

Audiometry findings, present regimen and length of aminoglycoside use in group I(n = 7) and II (n = 4) patients showing audiological evidence of hearing loss
Sr. No. (Group)	Length of treatment (Days)	Present regimen (Drugs)	PTA0	PTA2	PTA4	PTA6	PTA8	PTA10	PTAc

1 (I)	180	A, F, E, P, Py	N	N	N	HFL	HFL	HFL	HFL
2 (I)	60	A, F, E, P, Py	N	HFL	HFL	HFL	FLAT	FLAT	FLAT
3 (I)	180	A, F, E, P, Py	N	N	N	HFL	HFL	HFL	HFL
4 (I)	180	A, F, E, P, Py	N	N	N	HFL	HFL	FLAT	FLAT
5 (I)	180	A, F, E, P, Py	N	N	N	HFL	HFL	HFL	HFL
6 (I)	180	A, F, E, P, Py	N	N	N	HFL	HFL	HFL	HFL
7 (I)	180	A, F, E, P, Py	N	N	N	HFL	HFL	HFL	HFL
8 (II)	120	K, F, E, P, Py	N	N	N	HFL	FLAT	FLAT	FLAT
9 (II)	180	K, F, E, P, Py	N	N	N	HFL	HFL	HFL	HFL
10 (II)	180	K, F, E, P, Py	N	N	N	HFL	HFL	FLAT	FLAT
11 (II)	180	K, F, E, P, Py	N	N	N	HFL	HFL	HFL	HFL

A = amikacin, F = flouroquinolone, E = ethionamide, P = Para-amino salicylic acid, Py = Pyrazinamide, K = kanamycin, Days = days of aminoglycoside use in present regimen, PTA0 = baseline pure tone audiogram, PTA2 = pure tone audiogram after 2 months of aminoglycoside use, PTA4 = pure tone audiogram after 4 months of aminoglycoside use, PTA6 = pure tone audiogram after 6 months of aminoglycoside use, PTA8 = pure tone audiogram after 8 months of aminoglycoside use, PTA10 = pure tone audiogram after 10 months of aminoglycoside use, PTAc = pure tone audiogram after completion of therapy for MDR-TB, N = Normal, HFL = High frequency loss (hearing loss involving frequencies of 4000, 6000 and 8000 Hz), FLAT = Hearing loss involving frequencies in range of 250–3000 Hz along with involvement of 4000, 6000 and 8000 Hz (Criteria for hearing loss as defined in methods section).
Duggal and Sarkar BMC Ear, Nose and Throat Disorders 2007 7:5 doi:10.1186/1472-6815-7-5